A Phase 1 interventional study of Nasal Microbiota Transplant (NMT) and Placebo in Staphylococcal Aureus Infection, Microbial Colonization and Pediatric Infection, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 0 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Johns Hopkins University · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Communicable Diseases with a site in United States — 29 open to participants now, 43 under way, none of them phase 3. Communicable Diseases · United States.
Among the 161 studies in Communicable Diseases with a site in United States, this one is the 37th largest by planned enrollment of the 115 interventional ones that give a count, is one of 8 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 26 of the 40 other live ones, and was the 153rd registered.
628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.
Browse Communicable Diseases studies →29 of the 161 studies in Communicable Diseases with a site in United States are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18+
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of Minnesota · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
The University of Queensland · Sites in United States, Australia
Ages 2+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.
This study: 0 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 22 · Phase 3 12 · Phase 4 6
First in 1991; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 175 is above the median of 89 across 381 interventional studies indexed under Communicable Diseases.
Median enrollment 78 across the 115 interventional studies, 350 across the 44 observational. Of the 105 that completed or were terminated, 29 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 161 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 7 studies filed under Communicable Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Communicable Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT05401292University of Missouri-ColumbiaSkin Preparation for Elective Foot and Ankle Surgery | 2026-12 |
| NCT07043712University of Missouri-ColumbiaEffects of Pulse Consumption, Gut Microbiome, and Appetite in Healthy Participants | 2026-12-31 |
| NCT07287332Mayo ClinicBLOOM: Pragmatic Feasibility Trial | 2027-03 |
| NCT06546020Montana State UniversityGut Microbiota-dependent Health Impacts of Haskap Berries | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 161 studies in Communicable Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment
This parent-to-child NMT study will test the effect of an anterior nares, or nasal, microbiota transplant (NMT) on seeding, engraftment, and diversity of the neonatal microbiome following nasal decolonization for S. aureus. Infants admitted to the Johns Hopkins Neonatal Intensive Care Unit (NICU) will be screened and parents will be approached for enrollment in the study. After consent and baseline screening of parents and infants, eligible infants will undergo an NMT.
Child:
Inclusion criteria
Exclusion criteria
Donor:
Inclusion criteria
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Swab parent nares then insert swab directly into child nares once.
Biological: Nasal Microbiota Transplant (NMT)
Swab parents nares then insert swab directly into child nares multiple times.
Biological: Nasal Microbiota Transplant (NMT)
Insert a sterile swab into child nares.
Biological: Placebo
nasal microbiota transplant
Placebo sterile swab
Pediatric nasal microbiome diversity after parent-to-child NMT.
This outcome will be determined by analysis of periodic surveillance swabs collected after intervention.
Time frame: Day 2, 4, 7, 10, 14 days post-intervention
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 25 phase 1 interventional studies under Communicable Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.